10.01.24 -- Pharmaceutical Supply Chain Management Best Practices

Read more about how the pharmaceutical supply chain is a critical component of biologic product manufacturing.

Thorough characterization is key to unlocking the potential of antibody-based therapeutics. Leveraging a CDMO's extensive capabilities and expertise can allow you to navigate the biopharmaceutical development landscape.

The selection of representative cell lines for expressing bispecific antibodies (BsAbs) is a crucial initial development stage that significantly influences overall process yield and quality.

Learn how AI is transforming the biomanufacturing industry and how partnerships between pharmaceutical companies and academic institutions are poised to set the new standard.

Uncover a comprehensive framework for conducting robust comparability studies that ensure biosimilars meet stringent standards for safety, efficacy, and quality.

While the Brisbane facility’s key value is facilitating development and industrialization of new bacterial strains, how this is accomplished separates it from would-be competitors.

While AI is an exciting area for the biopharmaceutical sector, other shorter-term and more tangible things can be done to get life-saving medicines to market faster.

For the robust manufacturing of the serotype AAV6, the Pro10™ production platform has proven reliability and scalability, making it suitable for meeting the demands of large-scale manufacturing.

Gain valuable insights into the factors to consider when selecting a CDMO, such as experience, regulatory compliance, capacity, track record, and cultural fit.

Learn how controlling freezing rates, using specialized vials, and employing optimized stoppering techniques can reduce the risk of vial breakage during lyophilization and ensure high product quality.

As protein engineering and manufacturing technologies evolve, there's a need for flexible, customized strategies to accelerate drug development and approval of biotherapeutics.

The demand for biologics is projected to rise over the next decade. Explore the benefits of partnering with a CDMO as you aim to bring your drug to market.

See a quick visual summary of findings from an early feasibility clinical study featuring a 2-5 mL wearable injector with a viscous placebo.

As worldwide demand for biological therapies continues its path of significant growth, CMOs will continue to become an ever-increasing, critical element of the biopharmaceutical supply infrastructure.